Sentiment-Signal
8,0
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Unternehmen & Branche
| Name | NewAmsterdam Pharma Co N.V. |
|---|---|
| Ticker | NAMS |
| CIK | 0001936258 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 3,27 Mrd. USD |
| Beta | 0,13 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 22,503,000 | -203,819,000 | -1.72 | 769,284,000 | 683,431,000 |
| 2025-09-30 | 10-Q | 348,000 | -72,005,000 | -0.61 | 786,427,000 | 728,070,000 |
| 2025-06-30 | 10-Q | 19,145,000 | -17,364,000 | -0.15 | 815,112,000 | 778,497,000 |
| 2025-03-31 | 10-Q | 2,978,000 | -39,527,000 | -0.34 | 818,413,000 | 777,363,000 |
| 2024-12-31 | 10-K | 45,563,000 | -241,598,000 | -2.56 | 864,620,000 | 757,500,000 |
| 2024-09-30 | 10-Q | 29,111,000 | -16,647,000 | -0.18 | 439,191,000 | 378,862,000 |
| 2024-06-30 | 10-Q | 2,279,000 | -39,007,000 | -0.41 | 446,690,000 | 387,439,000 |
| 2024-03-31 | 10-Q | 1,401,000 | -93,767,000 | -1.06 | 488,463,000 | 411,803,000 |
| 2023-12-31 | 10-K | 14,090,000 | -176,937,000 | -2.15 | 347,097,000 | 288,393,000 |
| 2023-09-30 | 10-Q | 2,941,000 | -47,133,000 | -0.57 | 331,835,000 | |
| 2023-06-30 | 10-Q | 1,717,000 | -38,291,000 | -0.47 | 373,343,000 | |
| 2023-03-31 | 10-Q | 8,629,000 | -42,018,000 | -0.51 | 398,409,000 | |
| 2022-12-31 | 10-K | 102,694,000 | -22,634,000 | -1.19 | 478,497,000 | 430,066,000 |
| 2021-12-31 | 10-K | -41,785,000 | -3.81 | -113,816,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | Davidson Michael H. | Director, Officer, Chief Executive Officer | Open Market Sale | -443,707 | 33.25 | -14,753,257.75 | -807,1% | |
| 2026-02-26 | Davidson Michael H. | Director, Officer, Chief Executive Officer | Open Market Sale | -165,408 | 33.63 | -5,562,671.04 | -304,3% | |
| 2026-02-26 | Davidson Michael H. | Director, Officer, Chief Executive Officer | Open Market Sale | -17,924 | 34.44 | -617,302.56 | -33,8% | |
| 2026-02-25 | Davidson Michael H. | Director, Officer, Chief Executive Officer | Open Market Sale | -1,300 | 36.68 | -47,684.00 | -2,6% | |
| 2026-02-25 | Davidson Michael H. | Director, Officer, Chief Executive Officer | Open Market Sale | -46,517 | 35.11 | -1,633,211.87 | -89,3% | |
| 2026-02-25 | Davidson Michael H. | Director, Officer, Chief Executive Officer | Open Market Sale | -10,436 | 35.96 | -375,278.56 | -20,5% | |
| 2026-02-24 | Davidson Michael H. | Director, Officer, Chief Executive Officer | Open Market Sale | -61,547 | 36.13 | -2,223,693.11 | -121,6% | |
| 2026-02-24 | Davidson Michael H. | Director, Officer, Chief Executive Officer | Open Market Sale | -3,161 | 36.46 | -115,250.06 | -6,3% | |
| 2026-01-07 | Davidson Michael H. | Director, Officer, Chief Executive Officer | Open Market Sale | -11,582 | 0.00 | 0.00 | 0,0% | |
| 2025-09-15 | Topper James N | Director | Open Market Purchase | 660 | 23.70 | 15,638.90 | +0,9% | |
| 2025-08-11 | Topper James N | Director | Open Market Purchase | 471 | 23.98 | 11,293.97 | +0,6% | |
| 2025-06-25 | Topper James N | Director | Open Market Purchase | 1,260 | 18.26 | 23,011.63 | +1,3% | |
| 2025-06-24 | Topper James N | Director | Open Market Purchase | 2,520 | 18.43 | 46,454.44 | +2,5% | |
| 2025-06-16 | Topper James N | Director | Open Market Purchase | 8,584 | 19.50 | 167,381.13 | +9,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.